All News
Filter News
Found 242 articles
-
On the heels of positive Phase IIb data in plaque psoriasis, Takeda is acquiring both the therapy and Nimbus Lakshmi, a wholly owned subsidiary, in a potentially $6 billion deal.
-
Takeda to Acquire Nimbus Therapeutics’ Highly Selective, Allosteric TYK2 Inhibitor to Address Multiple Immune-Mediated Diseases
12/13/2022
Nimbus Therapeutics today announced that it has signed a definitive agreement under which Takeda (TSE:4502/NYSE:TAK) will acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858.
-
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
12/13/2022
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.
-
Nimbus reported positive Phase IIb results for NDI-034858 in moderate-to-severe plaque psoriasis, which researchers hope will have the efficacy of JAK inhibitors without the safety issues.
-
Nimbus Therapeutics Announces Positive Topline Results for Phase 2b Clinical Trial of Allosteric TYK2 Inhibitor in Psoriasis
11/30/2022
Nimbus Therapeutics today announced positive topline results from a Phase 2b clinical trial evaluating the allosteric TYK2 inhibitor NDI-034858 in patients with moderate-to-severe plaque psoriasis.
-
Computational Biology Market Size - Quantitative Research By QYResearch Medical
11/16/2022
The global computational biology market size reached USD 5.35 Billion in 2021 and is expected to register a revenue CAGR of 21.0% during the forecast period.
-
Schrödinger Reports Third Quarter 2022 Financial Results
11/3/2022
Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced financial results for the third quarter of 2022.
-
New Movers & Shakers took over the roles of chief executive officer, chief financial officer, chief medical officer and more at companies including Scenic Biotech, Biofrontera and X4 Pharmaceuticals.
-
Nimbus Therapeutics Appoints Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer
10/26/2022
Nimbus Therapeutics today announced the appointment of Nathalie Franchimont, M.D., Ph.D., as Chief Medical Officer.
-
Nimbus Therapeutics scored a $496 million payday through a collaboration and licensing deal with pharma giant Eli Lilly for potential therapeutics for metabolic diseases.
-
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Small Molecule Activators of AMPK
10/11/2022
Nimbus Therapeutics today announced it has entered into a research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company (Lilly) for the development and commercialization of novel targeted therapies that activate a specific isoform of AMPK for the treatment of metabolic diseases.
-
Computational technology company Schrödinger announced Thursday it has forged a $425 million drug design collaboration with Eli Lilly.
-
Schrödinger Hosts Platform Day
10/6/2022
Schrödinger is providing a detailed review of its technology platform, the impact of this platform across a growing portfolio of collaborative and proprietary drug discovery programs, areas for future innovation, and the opportunities for value creation during its Platform Day today, October 6, from 10:00 a.m. - 12:00 p.m. ET.
-
Pfizer is leveraging its funding and experience with vaccines, developing its meningococcal, flu, and RSV vaccines. It also announced its venture investment in Nimbus Therapeutics.
-
This week was rife with Series financings, which channeled money into innovative treatments for immune diseases and cancers, genomic treatments and precision healthcare.
-
Nimbus Therapeutics Closes $125M Private Financing to Advance Clinical Programs in Autoimmune Diseases and Oncology
9/12/2022
Nimbus Therapeutics today announced the closing of a $125 million private financing.
-
As the monkeypox outbreak continues in the U.S. and abroad, researchers and health officials race to test drugs against the disease. For that and more research stories, continue reading.
-
Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting
8/24/2022
Nimbus Therapeutics today presented research describing the chemical structure of NDI-034858, the company’s investigational oral allosteric TYK2 (tyrosine kinase 2) inhibitor now in two Phase 2b clinical studies for moderate-to-severe plaque psoriasis.
-
Schrödinger Reports Second Quarter 2022 Financial Results
8/4/2022
Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced financial results for the second quarter of 2022.
-
Clinical Laboratory Services Market Size US$ 232.6 Bn in 2022
7/27/2022
The global clinical laboratory services market was valued at US$ 232.6 Bn in 2022 and is anticipated to expand at a CAGR of 6.3% from 2022 to 2030.